- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
Patent holdings for IPC class A61P 9/04
Total number of patents in this class: 2178
10-year publication summary
|
55
|
60
|
95
|
130
|
124
|
130
|
153
|
156
|
158
|
131
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Cytokinetics, Inc. | 281 |
49 |
| Daiichi Sankyo Company, Limited | 1881 |
46 |
| Novartis AG | 10674 |
35 |
| Takeda Pharmaceutical Company Limited | 2713 |
33 |
| Amgen Inc. | 4147 |
32 |
| Osaka University | 3394 |
29 |
| Bristol-myers Squibb Company | 4847 |
26 |
| AstraZeneca AB | 2853 |
22 |
| Mitsubishi Tanabe Pharma Corporation | 563 |
22 |
| Boehringer Ingelheim International GmbH | 4649 |
19 |
| Cardioxyl Pharmaceuticals, Inc. | 49 |
19 |
| MyoKardia, Inc. | 121 |
18 |
| Boehringer Ingelheim Vetmedica GmbH | 1277 |
17 |
| Bayer Pharma AG | 1055 |
17 |
| Shionogi & Co., Ltd. | 840 |
14 |
| Sunshine Lake Pharma Co., Ltd. | 600 |
14 |
| Imbria Pharmaceuticals, Inc. | 66 |
14 |
| Bayer AG | 3381 |
13 |
| Japan Tobacco Inc. | 3604 |
13 |
| The Regents of the University of California | 20211 |
12 |
| Other owners | 1714 |